SCHEMBL292284

SCHEMBL292284

O=C(O)CCCCCN1C(=O)c2ccc(C(=O)O)cc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 1.00
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
GAA P10253 2/20 0.62
CASP1 P29466 1/20 0.62
HSD17B10 Q99714 1/20 0.62
ALDH1A1 P00352 2/20 0.60
POLB P06746 2/20 0.60
TSHR P16473 1/20 0.57
HPGD P15428 1/20 0.56
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA4 P22748 1/20 0.52
CA9 Q16790 1/20 0.52
ENPP2 Q13822 1/20 0.51
PTGS1 P23219 4/20 0.50
PTGS2 P35354 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17973600 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KMT2AMEN1GAACASP1
SCHEMBL4230728 0.99 SMN1; SMN2 (0.97) SMN1; SMN2KMT2AMEN1GAACASP1
SCHEMBL4235238 0.94 SMN1; SMN2 (0.89) SMN1; SMN2KMT2AMEN1GAACASP1
SCHEMBL5864233 0.93 SMN1; SMN2 (0.86) SMN1; SMN2KMT2AMEN1GAACASP1
SCHEMBL13647686 0.89 SMN1; SMN2 (0.80) SMN1; SMN2KMT2AMEN1GAACASP1
SCHEMBL4235113 0.88 SMN1; SMN2 (0.78) SMN1; SMN2KMT2AMEN1GAACASP1
SCHEMBL9201916 0.87 SMN1; SMN2 (0.77) SMN1; SMN2KMT2AMEN1GAAHSD17B10
SCHEMBL11033307 0.87 SMN1; SMN2 (0.77) SMN1; SMN2KMT2AMEN1GAAHSD17B10
SCHEMBL11724761 0.87 SMN1; SMN2 (0.77) SMN1; SMN2KMT2AMEN1GAAHSD17B10
SCHEMBL8335250 0.87 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1GAACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7009027-B2 Graft polymers formed by using polyesterimides having cyclic dicarboxylic anhydride end groups; blends used to form carpet filaments or fibers THUERINGISCHES INSTITUT FUER TEXTIL-UND KUNSTSTOFF-FORSCHUNG E.V. (DE) 2006-03-07 US claimed
EP-1339773-B1 METHOD FOR PRODUCING MELTABLE POLYESTERS THUERINGISCHES INST TEXTIL (DE) 2005-02-02 EP claimed
US-20040039137-A1 Graft polymers formed by using polyesterimides having cyclic dicarboxylic anhydride end groups; blends used to form carpet filaments or fibers THUERINGISCHES INSTITUT FUER TEXTIL-UND KUNSTSTOFF-FORSCHUNG E.V. (DE) 2004-02-26 US claimed
EP-1339773-A2 METHOD FOR PRODUCING MELTABLE POLYESTERS THÜRINGISCHES INSTITUT FÜR TEXTIL- UND KUNSTSTOFF-FORSCHUNG E.V. (DE) 2003-09-03 EP claimed
WO-2002042353-A2 METHOD FOR PRODUCING MELTABLE POLYESTERS THÜRINGISCHES INSTITUT FÜR TEXTIL - UND KUNSTSTOFF - FORSCHUNG E.V. (DE) 2002-05-30 WO claimed
EP-2008674-B1 Catheters and Catheter shafts made from liquid crystal polymer blends BOSTON SCIENT LTD (BB) 2012-03-14 EP disclosed
US-20090215814-A1 Method of inhibiting neurotrophin-receptor binding QUEEN'S UNIVERSITY AT KINGSTON (CA) 2009-08-27 US disclosed
EP-2008674-A1 Balloons made from liquid crystal polymer blends Boston Scientific Limited (BB) 2008-12-31 EP disclosed
EP-1467776-B1 BALLOONS MADE FROM LIQUID CRYSTAL POLYMER BLENDS BOSTON SCIENT LTD (BB) 2008-10-08 EP disclosed
US-20070078137-A1 Method of inhibiting neurotrophin-receptor binding QUEEN'S UNIVERSITY AT KINGSTON (CA) 2007-04-05 US disclosed
US-7148352-B2 Method of inhibiting neurotrophin-receptor binding QUEEN'S UNIVERSITY AT KINGSTON (CA) 2006-12-12 US disclosed
US-7009027-B2 Graft polymers formed by using polyesterimides having cyclic dicarboxylic anhydride end groups; blends used to form carpet filaments or fibers THUERINGISCHES INSTITUT FUER TEXTIL-UND KUNSTSTOFF-FORSCHUNG E.V. (DE) 2006-03-07 US disclosed
US-20030138577-A1 Balloons made from liquid crystal polymer blends BOSTON SCIENTIFIC SCIMED, INC. 2003-07-24 US disclosed
US-6468990-B1 ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES QUEEN'S UNIVERSITY AT KINGSTON (CA) 2002-10-22 US disclosed
EP-1226121-A1 METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING QUEEN'S UNIVERSITY AT KINGSTON (CA) 2002-07-31 EP disclosed
WO-2002042353-A2 METHOD FOR PRODUCING MELTABLE POLYESTERS THÜRINGISCHES INSTITUT FÜR TEXTIL - UND KUNSTSTOFF - FORSCHUNG E.V. (DE) 2002-05-30 WO disclosed
WO-2000069829-A1 METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING QUEEN'S UNIVERSITY (CA) 2000-11-23 WO disclosed
US-5994284-A REACTING PHTHALIC ACID OR ANHYDRIDE WITH CAPROLACTAM; OXIDATION WITH HYDROGEN PEROXIDE CLARIANT GMBH (DE) 1999-11-30 US disclosed
US-4388456-A FOOD PACKAGING EASTMAN KODAK COMPANY (US) 1983-06-14 US disclosed
US-4041065-A WIRE COATINGS, FILMS, MOLDINGS STANDARD OIL COMPANY (INDIANA) (US) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215814-A1 Method of inhibiting neurotrophin-receptor binding NGF, NTRK2, BDNF SMN1; SMN2 707/4885KMT2A 3466/4885MEN1 3489/4885
US-20070078137-A1 Method of inhibiting neurotrophin-receptor binding NGF, NTRK2, BDNF SMN1; SMN2 707/4885KMT2A 3466/4885MEN1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.